Nigel Capps

4.4k total citations
34 papers, 1.7k citations indexed

About

Nigel Capps is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, Nigel Capps has authored 34 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Surgery, 8 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Economics and Econometrics. Recurrent topics in Nigel Capps's work include Lipoproteins and Cardiovascular Health (18 papers), Cancer, Lipids, and Metabolism (8 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Nigel Capps is often cited by papers focused on Lipoproteins and Cardiovascular Health (18 papers), Cancer, Lipids, and Metabolism (8 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Nigel Capps collaborates with scholars based in United Kingdom, Qatar and New Zealand. Nigel Capps's co-authors include Paul N. Durrington, Lee Hooper, George Davey Smith, Rudolph A. Riemersma, Shah Ebrahim, Carolyn Summerbell, Steve E. Humphries, Andy Ness, Helen V Worthington and Roger Harrison and has published in prestigious journals such as Cochrane Database of Systematic Reviews, European Heart Journal and Clinical Chemistry.

In The Last Decade

Nigel Capps

34 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nigel Capps United Kingdom 17 865 426 409 300 294 34 1.7k
Michael S. Kostapanos Greece 25 1.1k 1.2× 801 1.9× 509 1.2× 491 1.6× 314 1.1× 79 2.5k
Emma A. Meagher United States 16 683 0.8× 393 0.9× 216 0.5× 322 1.1× 244 0.8× 47 1.8k
Manuela Casula Italy 22 738 0.9× 449 1.1× 194 0.5× 337 1.1× 166 0.6× 87 1.8k
Evangelos C. Rizos Greece 23 575 0.7× 611 1.4× 541 1.3× 415 1.4× 210 0.7× 77 2.2k
Alice Dowdy United States 13 1.1k 1.3× 977 2.3× 285 0.7× 379 1.3× 285 1.0× 17 2.1k
Marcelo Chiara Bertolami Brazil 25 685 0.8× 385 0.9× 133 0.3× 345 1.1× 193 0.7× 71 1.9k
Payal Kohli United States 19 890 1.0× 247 0.6× 375 0.9× 371 1.2× 146 0.5× 43 2.0k
Uffe Ravnskov Sweden 23 532 0.6× 375 0.9× 164 0.4× 186 0.6× 295 1.0× 75 1.9k
Chizuko Maruyama Japan 20 405 0.5× 397 0.9× 204 0.5× 310 1.0× 88 0.3× 72 1.5k
Rocío Mateo‐Gállego Spain 22 578 0.7× 636 1.5× 192 0.5× 367 1.2× 187 0.6× 92 1.8k

Countries citing papers authored by Nigel Capps

Since Specialization
Citations

This map shows the geographic impact of Nigel Capps's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nigel Capps with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nigel Capps more than expected).

Fields of papers citing papers by Nigel Capps

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nigel Capps. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nigel Capps. The network helps show where Nigel Capps may publish in the future.

Co-authorship network of co-authors of Nigel Capps

This figure shows the co-authorship network connecting the top 25 collaborators of Nigel Capps. A scholar is included among the top collaborators of Nigel Capps based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nigel Capps. Nigel Capps is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Connolly, Derek, et al.. (2023). Assessing opinion on lower LDL-cholesterol lowering, and the role of newer lipid-reducing treatment options. British Journal of Cardiology. 30(2). 14–14. 1 indexed citations
3.
Joharatnam‐Hogan, Nalinie, Leo Alexandre, James Yarmolinsky, et al.. (2021). Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs. Current Oncology Reports. 23(3). 29–29. 24 indexed citations
4.
5.
Soran, Handrean, Jackie A. Cooper, Paul N. Durrington, et al.. (2020). Non-HDL or LDL cholesterol in heterozygous familial hypercholesterolaemia: findings of the Simon Broome Register. Current Opinion in Lipidology. 31(4). 167–175. 3 indexed citations
6.
Cegla, Jaimini, R. Dermot G. Neely, Michael France, et al.. (2019). HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis. 291. 62–70. 156 indexed citations
7.
Humphries, Steve E., Jackie A. Cooper, Nigel Capps, et al.. (2018). Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register. Atherosclerosis. 281. 207–212. 22 indexed citations
8.
Humphries, Steve E., Jackie A. Cooper, Mary Seed, et al.. (2018). Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register. Atherosclerosis. 274. 41–46. 72 indexed citations
9.
Schofield, Jonathan, See Kwok, Michael France, et al.. (2016). Knowledge gaps in the management of familial hypercholesterolaemia. A UK based survey. Atherosclerosis. 252. 161–165. 17 indexed citations
10.
Neil, H. A. W., D. James Cooper, D. J. Betteridge, et al.. (2010). All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study. Atherosclerosis. 211(2). 618–623. 24 indexed citations
11.
Ramachandran, Sudarshan, et al.. (2010). Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes. Annals of Clinical Biochemistry International Journal of Laboratory Medicine. 48(1). 75–78. 4 indexed citations
12.
Tahrani, Abd A., Mary McCarthy, Sarah Taylor, et al.. (2008). Impact of practice size on delivery of diabetes care before and after the Quality and Outcomes Framework implementation. British Journal of General Practice. 58(553). 576–579. 16 indexed citations
13.
Neil, Andrew, J.A. Cooper, J. Betteridge, et al.. (2008). Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. European Heart Journal. 29(21). 2625–2633. 327 indexed citations
14.
Capps, Nigel. (2006). Total and low-density lipoprotein cholesterol responses to ezetimibe in clinical practice. International Journal of Clinical Practice. 60(7). 867–869. 8 indexed citations
15.
Hooper, Lee, Rachel Thompson, Roger Harrison, et al.. (2006). Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ. 332(7544). 752–760. 481 indexed citations
16.
Weston, Clive, et al.. (2005). This house believes that the UK healthcare system may be failing as many as 50% of patients with hyperlipidaemia by not reducing their cholesterol to effective levels: A debate. Cronfa (Swansea University). 1 indexed citations
17.
Capps, Nigel, L N Sandle, Brian L. Smith, et al.. (2001). External quality assessment of laboratory performance in analysis of toxicological cases. Forensic Science International. 121(1-2). 27–32. 3 indexed citations
18.
Hooper, Lee, Carolyn Summerbell, Julian P. T. Higgins, et al.. (2000). Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database of Systematic Reviews. CD002137–CD002137. 74 indexed citations
19.
Thomson, Alison H., Ian D. Watson, John F. Wilson, et al.. (1998). An Audit of Therapeutic Drug Monitoring Service Provision by Laboratories Participating in an External Quality Assessment Scheme. Therapeutic Drug Monitoring. 20(3). 248–252. 6 indexed citations
20.
Capps, Nigel, et al.. (1990). GENERAL PRACTICE THEOPHYLLINE AUDIT IN THE EXETER HEALTH DISTRICT. Journal of Clinical Pharmacy and Therapeutics. 15(2). 101–107. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael S. Kostapanos Breakdown of academic impact, for papers by Emma A. Meagher Breakdown of academic impact, for papers by Manuela Casula Breakdown of academic impact, for papers by Evangelos C. Rizos Breakdown of academic impact, for papers by Alice Dowdy Breakdown of academic impact, for papers by Marcelo Chiara Bertolami Breakdown of academic impact, for papers by Payal Kohli Breakdown of academic impact, for papers by Uffe Ravnskov Breakdown of academic impact, for papers by Chizuko Maruyama Breakdown of academic impact, for papers by Rocío Mateo‐Gállego
Rankless by CCL
2026